This nonrandomized clinical trial examines the safety and efficacy of guanylate cyclase-C (GCC) chimeric antigen receptor T-cell therapy in patients with metastatic colorectal cancer. The gene discussed is NPR3; the disease is metastatic colorectal cancer.